Pelthos Therapeutics Net Income Over Time
| PTHS Stock | 22.99 0.33 1.42% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pelthos Therapeutics Performance and Pelthos Therapeutics Correlation. Is there potential for Pharmaceuticals market expansion? Will Pelthos introduce new products? Factors like these will boost the valuation of Pelthos Therapeutics. Anticipated expansion of Pelthos directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Pelthos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pelthos Therapeutics is measured differently than its book value, which is the value of Pelthos that is recorded on the company's balance sheet. Investors also form their own opinion of Pelthos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pelthos Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Pelthos Therapeutics' market value can be influenced by many factors that don't directly affect Pelthos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pelthos Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pelthos Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pelthos Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Pelthos Therapeutics and related stocks such as CASI Pharmaceuticals, Lisata Therapeutics, and Clearside Biomedical Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CASI | (20 K) | (4.6 M) | (14.5 M) | (5.7 M) | (26.2 M) | (7.2 M) | (9.5 M) | (10.8 M) | (27.5 M) | (45.4 M) | (48.3 M) | (36.7 M) | (41 M) | (26.9 M) | (39.3 M) | (35.3 M) | (33.6 M) |
| LSTA | (2.7 M) | (47.1 M) | (54.8 M) | (39 M) | (54.9 M) | (80.9 M) | (32.7 M) | 23 M | (16.2 M) | (20.1 M) | (8.2 M) | (27.5 M) | (54.2 M) | (20.8 M) | (20 M) | (18 M) | (18.9 M) |
| KAPA | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.1 M) | (1.1 M) | (1.8 M) | (2.6 M) | (2.3 M) | (2.5 M) |
| LEXX | (508.3 K) | (343.6 K) | (343.6 K) | (1.9 M) | (1.8 M) | (1.2 M) | (1.9 M) | (6.6 M) | (4.1 M) | (3.9 M) | (4 M) | (7.3 M) | (6.7 M) | (5.8 M) | (11.9 M) | (10.7 M) | (10.2 M) |
| PASG | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (45.6 M) | (112.2 M) | (185.4 M) | (136.1 M) | (102.1 M) | (64.8 M) | (58.3 M) | (61.2 M) |
| LIXT | (32.9 K) | (2.1 M) | (3.6 K) | (1.4 M) | (2.8 M) | (2.9 M) | (2.1 M) | (1.8 M) | (2.1 M) | (2.4 M) | (3.3 M) | (6.7 M) | (6.3 M) | (5.1 M) | (3.6 M) | (3.2 M) | (3.4 M) |
| ENLV | (229 K) | (229 K) | (229 K) | (1.1 M) | (7 M) | (15.4 M) | (16 M) | (5.9 M) | (4.9 M) | (9.4 M) | (11.8 M) | (14.5 M) | (31.1 M) | (29.1 M) | (15 M) | (13.5 M) | (14.2 M) |
| MTVA | (320 K) | (320 K) | (320 K) | (320 K) | (320 K) | (9 M) | (14.6 M) | (33.4 M) | (15.5 M) | (21.3 M) | (29.7 M) | (15.3 M) | (14 M) | (12.5 M) | (27.6 M) | (24.8 M) | (26.1 M) |
| CING | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (7.2 M) | (20.7 M) | (17.9 M) | (23.5 M) | (15.5 M) | (14 M) | (14.7 M) |
Pelthos Therapeutics and related stocks such as CASI Pharmaceuticals, Lisata Therapeutics, and Clearside Biomedical Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Pelthos Therapeutics financial statement analysis. It represents the amount of money remaining after all of Pelthos Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Pelthos Therapeutics | PTHS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 4020 Stirrup Creek |
| Exchange | NYSE MKT Exchange |
null 22.99
Additional Tools for Pelthos Stock Analysis
When running Pelthos Therapeutics' price analysis, check to measure Pelthos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pelthos Therapeutics is operating at the current time. Most of Pelthos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pelthos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pelthos Therapeutics' price. Additionally, you may evaluate how the addition of Pelthos Therapeutics to your portfolios can decrease your overall portfolio volatility.